Explore the benefits and challenges of bringing an in-house molecular test to market, with real-world examples
Many laboratories around the world have adopted expanded diagnostic testing capabilities to address the coronavirus pandemic and are now seeking ways to expand testing with additional workflows for infectious disease syndromic panels, pharmacogenomic analysis, oncology testing, and more.
Historically, developing a molecular test within a clinical laboratory has been perceived as a complicated and laborious process. In this webinar series, we aim to dispel common misconceptions of laboratory developed tests (LDTs) by inviting industry experts to share about the advantages, design and implementation process, and establishment of LDTs in clinical laboratories. Learn about how the flexibility of in-house molecular-based tests can help a clinical laboratory impact patient outcome and remain competitive.
The Simple, Sensible, Salient & Still Spell-Binding Seven Questions about Laboratory Developed Tests
- Describe different types of in-vitro diagnostic tests
- Identify differences between laboratory developed tests (LDT) and in-vitro diagnostic (IVD) tests
- List the benefits of running LDTs and IVDs
- Explain how laboratory developed tests are designed and regulated in the US
Challenges of Establishing Laboratory-Developed Tests
- Describe advantages of implementing a laboratory-developed test
- List decision criteria for assay design and target selection
- Recall analytical and clinical validation considerations